Data-driven Clustering of Neurodegenerative diseases based on EEG Spectrum power-law decay: the DaCNES Study.
Objective: To test accuracy of the power law exponent β applied to EEG in differentiating neurodegenerative diseases and to explore differences in neuronal connectivity among…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…An analysis of gender differences in the clinical profile of Parkinson’s Disease patients
Objective: The present study aimed at characterising in depth the overall clinical profile of male and females PD patients. Background: Parkinson Disease (PD) is the…Cholinergic deficits in Parkinson Disease
Objective: To determine whether loss of cholinergic projections to cortical and limbic regions contributes to the development of dementia in Parkinson’s disease (PD). Background: PD…Subjective cognitive decline and Frailty in an Asian cohort of patients with Parkinson’s Disease
Objective: To assess the prevalence of subjective cognitive decline (SCD) and to look for its association with frailty in an Asian cohort of patients with…Burden and management of tardive dyskinesia (TD): a cross-sectional international survey study to assess the perceptions and experiences of patients with TD
Objective: To assess patient perceptions of and experiences with TD and its impact on their daily functioning and quality of life (QoL). Background: There is…Utility of neurophysiological markers in clinical management of subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson’s disease (PD)-a case report.
Objective: Use local field potentials (LFP) to inform longitudinal clinical decision making. Background: Genetic status, clinical and stimulation parameters affect outcomes in PD STN DBS.…Clinical-based diagnosis and self-reported Parkinson’s disease in a population-based sample in southern Brazil
Objective: To report the frequency of self-reported PD and the diagnostic evaluation performed by clinical neurologists in a population-based cohort from south Brazil. Background: It…Challenges with oral anti-parkinsonian medications and opportunities with continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDP/CDP) for treatment of advanced Parkinson’s Disease (aPD)
Objective: To understand people with Parkinson’s (PwP) experience with their advancing disease and identify factors for PwP to initiate and continue on LDP/CDP as treatment…The Roche ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development – Focus on Parkinson’s disease
Objective: To develop an ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development to increase the probability of success of clinical trials in Parkinson’s disease. Background:…
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 186
- Next Page »